» Articles » PMID: 16636275

Conversion to the Amyotrophic Lateral Sclerosis Phenotype is Associated with Intermolecular Linked Insoluble Aggregates of SOD1 in Mitochondria

Overview
Specialty Science
Date 2006 Apr 26
PMID 16636275
Citations 213
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty percent of the familial form of amyotrophic lateral sclerosis (ALS) is caused by mutations in the Cu, Zn-superoxide dismutase gene (SOD1) through the gain of a toxic function. The nature of this toxic function of mutant SOD1 has remained largely unknown. Here we show that WT SOD1 not only hastens onset of the ALS phenotype but can also convert an unaffected phenotype to an ALS phenotype in mutant SOD1 transgenic mouse models. Further analyses of the single- and double-transgenic mice revealed that conversion of mutant SOD1 from a soluble form to an aggregated and detergent-insoluble form was associated with development of the ALS phenotype in transgenic mice. Conversion of WT SOD1 from a soluble form to an aggregated and insoluble form also correlates with exacerbation of the disease or conversion to a disease phenotype in double-transgenic mice. This conversion, observed in the mitochondrial fraction of the spinal cord, involved formation of insoluble SOD1 dimers and multimers that are crosslinked through intermolecular disulfide bonds via oxidation of cysteine residues in SOD1. Our data thus show a molecular mechanism by which SOD1, an important protein in cellular defense against free radicals, is converted to aggregated and apparently ALS-associated toxic dimers and multimers by redox processes. These findings provide evidence of direct links among oxidation, protein aggregation, mitochondrial damage, and SOD1-mediated ALS, with possible applications to the aging process and other late-onset neurodegenerative disorders. Importantly, rational therapy based on these observations can now be developed and tested.

Citing Articles

Disulfide-mediated oligomerization of mutant Cu/Zn-superoxide dismutase associated with canine degenerative myelopathy.

Shino Y, Muraki N, Kobatake Y, Kamishina H, Kato R, Furukawa Y Protein Sci. 2024; 33(12):e5210.

PMID: 39548731 PMC: 11568243. DOI: 10.1002/pro.5210.


VDAC1-Based Peptides as Potential Modulators of VDAC1 Interactions with Its Partners and as a Therapeutic for Cancer, NASH, and Diabetes.

Shteinfer-Kuzmine A, Santhanam M, Shoshan-Barmatz V Biomolecules. 2024; 14(9).

PMID: 39334905 PMC: 11430116. DOI: 10.3390/biom14091139.


Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS.

Tsekrekou M, Giannakou M, Papanikolopoulou K, Skretas G Front Mol Biosci. 2024; 11:1383453.

PMID: 38855322 PMC: 11157337. DOI: 10.3389/fmolb.2024.1383453.


Ebselen analogues delay disease onset and its course in fALS by on-target SOD-1 engagement.

Watanabe S, Amporndanai K, Awais R, Latham C, Awais M, ONeill P Sci Rep. 2024; 14(1):12118.

PMID: 38802492 PMC: 11130262. DOI: 10.1038/s41598-024-62903-5.


Amyotrophic Lateral Sclerosis-Associated Mutants of SOD1 Perturb mRNA Splicing through Aberrant Interactions with SRSF2.

Chen X, Cao Z, Wang Y Anal Chem. 2024; 96(23):9713-9720.

PMID: 38795036 PMC: 11412154. DOI: 10.1021/acs.analchem.4c01770.


References
1.
Chang L, Slot J, Geuze H, Crapo J . Molecular immunocytochemistry of the CuZn superoxide dismutase in rat hepatocytes. J Cell Biol. 1988; 107(6 Pt 1):2169-79. PMC: 2115655. DOI: 10.1083/jcb.107.6.2169. View

2.
Jonsson P, Ernhill K, Andersen P, Bergemalm D, Brannstrom T, Gredal O . Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. Brain. 2003; 127(Pt 1):73-88. DOI: 10.1093/brain/awh005. View

3.
Watanabe Y, Yasui K, Nakano T, Doi K, Fukada Y, Kitayama M . Mouse motor neuron disease caused by truncated SOD1 with or without C-terminal modification. Brain Res Mol Brain Res. 2005; 135(1-2):12-20. DOI: 10.1016/j.molbrainres.2004.11.019. View

4.
Wang J, Xu G, Li H, Gonzales V, Fromholt D, Karch C . Somatodendritic accumulation of misfolded SOD1-L126Z in motor neurons mediates degeneration: alphaB-crystallin modulates aggregation. Hum Mol Genet. 2005; 14(16):2335-47. DOI: 10.1093/hmg/ddi236. View

5.
Beal M . Oxidatively modified proteins in aging and disease. Free Radic Biol Med. 2002; 32(9):797-803. DOI: 10.1016/s0891-5849(02)00780-3. View